WAY

Waystar Holding Corp. 10-Q Summary: Q2 2025

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2025. Waystar Holding Corp. is a provider of mission-critical cloud technology for healthcare organizations, focusing on payment processing, claim accuracy, and patient payment solutions. The company operates as a single reportable segment and serves over 30,000 clients, including 16 of the top 20 U.S. News Best Hospitals. As of July 21, 2025, the company had 174,238,972 shares of common stock outstanding.

Key Financial Metrics

Material Changes vs. Prior Period

• Profitability Turnaround: The company reported a net income of $32.2 million in Q2 2025, a significant improvement from a net loss of $27.7 million in Q2 2024. This shift was driven by revenue growth and a substantial reduction in interest expense.
• Revenue Growth: Revenue increased 15.4% year-over-year in Q2 2025. Subscription revenue grew 16.7% and volume-based revenue grew 14.4%, driven by expansion of existing client usage and new client acquisitions.
• Interest Expense Reduction: Total interest expense decreased by 64.8% in Q2 2025 compared to the prior year. This was primarily due to the repayment of $1.0 billion in principal on the First Lien Credit Facility using IPO proceeds in 2024.
• Expense Management: General and Administrative (G&A) expenses decreased 26.9% year-over-year, largely due to the non-recurrence of $13.6 million in stock-based compensation related to performance condition options that vested upon the IPO in the prior year.
• Depreciation & Amortization: D&A expenses decreased 24.5% year-over-year as several intangible assets became fully amortized in the prior year.

Guidance, Outlook, and Risks

• Acquisition of Iodine: On July 23, 2025, Waystar entered into an agreement to acquire Iodine Software Holdings, Inc. for $1.25 billion ($625 million cash and stock). The acquisition is expected to close by year-end 2025 and aims to bolster AI leadership in clinical intelligence.
• Secondary Offerings: Institutional Investors completed two secondary offerings in early 2025 (February and May). The Company did not receive proceeds from these sales but paid certain expenses on behalf of selling stockholders.
• Tax Legislation: The "One Big Beautiful Bill Act" (H.R.1) was signed into law on July 4, 2025, impacting corporate tax rates and R&D treatment. The company is evaluating the effect on future financial statements.
• Risk Factors: Key risks include the highly competitive healthcare technology industry, dependence on senior management, regulatory changes in healthcare and data privacy, and the ability to successfully integrate the Iodine acquisition.

Investor Verification Checklist

• Debt Covenants: Verify continued compliance with debt covenants, specifically regarding collection thresholds for the Receivables Facility and restrictions on additional indebtedness.
• Acquisition Integration: Monitor the closing timeline and integration progress of the $1.25 billion Iodine acquisition, including potential accounting conclusions and synergy realization.
• Stock-Based Compensation: Review future stock-based compensation expenses, noting the reduction in non-recurring IPO-related charges and the ongoing vesting of new equity awards (RSUs, PSUs).
• Interest Rate Exposure: Assess the impact of interest rate fluctuations on the remaining variable-rate debt, despite the use of interest rate swaps to hedge a portion of the exposure.
• Net Revenue Retention: Track the Net Revenue Retention Rate (114.6%) to ensure continued organic growth from the existing client base remains robust.